Company Press Releases

23 April 2026

FLAG Therapeutics presents a poster entitled “Formulation of FLAG-003 Tablets to Support Phase I/II Clinical Testing in Children with DIPG” at the 2026 AACR Brain Cancer Conference

31 Oct 2025

FLAG Therapeutics Secures Over $500,000 in Equity and Impact Funding from Venture and Mission-Driven Investors, Including Springhood Ventures, Kids Beating Cancer, The Musella Foundation, the AYJ Fund, Tough2gether Foundation and DDRFA

31 Jan 2023

FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)

8 Aug 2017

FLAG Therapeutics Oversubscribes Financing Round and Receives $500,000 Matching Loan From North Carolina Biotechnology Center

29 Feb 2016

FLAG Therapeutics Granted Orphan Drug Designation for FLAG-003 for the Treatment of Glioma

16 Jul 2024

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

FLAG in the News

17 Nov 2019

NEW PANCREATIC CANCER TREATMENT TARGETS ONLY TUMOR CELLS